About Us
Company Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Approach
The Opportunity in China
The Everest Advantage
Partners
Pipeline
Media
Investors
News
Search
18
2021/01
Everest Medicines Announces Amended Agreement with Spero Therapeutics
06
2021/01
Everest Medicines Initiates Submission of New Drug Application in Singapore for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
06
2021/01
Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy for Metastatic Urothelial Cancer
22
2020/12
Everest Medicines Appoints Lan Kang to Board of Directors
09
2020/12
Everest Medicines Announces First Patient Dosed in Phase 3 Registration Asian Study of Trodelvy
™
(sacituzumab govitecan) for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
02
2020/12
Everest Medicines Announces The China Center for Drug Evaluation, National Medical Products Administration Recommends Breakthrough Therapy Designation for Nefecon for the Treatment of IgA Nephropathy
10
2020/11
Everest Medicines Announces that Licensing Partner Calliditas Therapeutics has Reported Positive Topline Results from Pivotal Phase 3 NefIgArd Trial
03
2020/11
Everest Medicines Announces First Patient Dosed in its Phase 2b Registration Clinical Trial of Trodelvy
™
(sacituzumab govitecan) for Metastatic Triple-Negative Breast Cancer in China
02
2020/11
Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration for Phase 3 Registration Trial of Trodelvy
™
for Metastatic Breast Cancer in China
08
2020/10
Everest Medicines Announces the Offer Price and Allotment Results of the Global Offering
25
2020/09
Everest Medicines Announced Its Global Offering and Proposed Listing on the Stock Exchange of Hong Kong
15
2020/09
Everest Medicines Announces Top-line Results from Phase 1 Clinical Trial of Taniborbactam in Combination with Cefepime in China
<<
<
1
2
3
4
5
6
7
8
9
>
>>
Copyright Everest Medicines 2020 云顶药业（苏州）有限公司
苏ICP备20038571号
|
Terms of Use
|
Privacy Policy
|
Disclaimers
沪公网安备 31010602006477号
